NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Curon Biopharmaceutical

Curon Biopharmaceutical

Private
ShanghaiHealthcare & Life Scienceshttps://curonbiopharma.com

Last Round

M&A

Oct 1, 2024

Est. Valuation

$214M

Total Funding Raised

$250M

Company Overview

Curon Biopharmaceutical is a biotechnology company that develops innovative cancer immunotherapies, including bispecific antibodies and antibody-drug conjugates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalbispecific antibodyB-cell depletionclinical-stage biotechdrug licensingoncology therapyautoimmune diseasebiotech startupasset divestiturebiologics discoverypharma R&Ddrug pipelineclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Curon Biopharmaceutical Comparables

Compare Curon Biopharmaceutical with similar companies based on industry and business-model similarity.

Curon Biopharmaceutical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cullinan Oncology
80%
Gilead Sciences
78%
EpimAb Biotherapeutics
78%

Curon Biopharmaceutical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AOct 1, 2024
Series BDec 28, 2019
Series AJul 27, 2018

Curon Biopharmaceutical Investors

Notable investors and investment history

Curon Biopharmaceutical investors
InvestorRounds
DYEE CapitalSeries B
Boyu CapitalSeries A
TemasekSeries A
Oriza HoldingsSeries B
Hillhouse InvestmentSeries B
Shengshan Asset ManagementSeries B
Lilly Asia VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 28, 2024

    Grew 67% QoQ, from 6 to 10 employees.

Curon Biopharmaceutical Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Curon Biopharmaceutical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Curon Biopharmaceutical's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range8
Year Founded2018
Last FundingOct 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.